Patent Case Watch

Patent opinions from the Eastern District of Texas and the U.S. Court of Appeals for the Federal Circuit

Fed. Cir.

Bayer HealthCare LLC v. Baxalta Inc., No. 19-2418 (Fed. Cir. Mar. 1, 2021)

Affirmed
Infringement Enablement Damages Willfulness
Court
U.S. Court of Appeals for the Federal Circuit
Case No.
No. 19-2418
Also Docketed
No. 20-1017 (consolidated; same document)
Decided
March 1, 2021
Judge
Stoll, J.
Document
Precedential Opinion
Length
37 pages

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

This patent infringement case presents various issues of claim scope, infringement, validity, and damages. Bayer HealthCare LLC sued Baxalta Inc. and Baxalta US Inc. (collectively, “Baxalta”) and Nektar Therapeutics, alleging that Baxalta’s biologic product Adynovate ® infringes cer- tain claims of Bayer’s U.S. Patent No. 9,364,520. The jury found that the asserted claims were enabled and infringed, and that Bayer was entitled to reasonable -royalty dam- ages.

Download Opinion (PDF)

Source: govinfo.gov USCOURTS collection · retrieved July 23, 2026 · Report an error